Cargando…
Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma
SIMPLE SUMMARY: Osteosarcoma is the most common form of primary solid bone malignancy, with the highest incidence in adolescence. The therapeutic management includes surgical resection combined with adjuvant/neoadjuvant chemotherapy regimens. Despite this multimodal combination, about two patients o...
Autores principales: | Mangelinck, Adèle, Habel, Nadia, Mohr, Audrey, Gaspar, Nathalie, Stefanovska, Bojana, Fromigué, Olivia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616540/ https://www.ncbi.nlm.nih.gov/pubmed/34831022 http://dx.doi.org/10.3390/cancers13225869 |
Ejemplares similares
-
MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma
por: Mangelinck, Adèle, et al.
Publicado: (2019) -
CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process
por: Habel, Nadia, et al.
Publicado: (2019) -
Tribbles Pseudokinase 3 Regulation and Contribution to Cancer
por: Stefanovska, Bojana, et al.
Publicado: (2021) -
Recent advances in understanding osteosarcoma and emerging therapies
por: Gaspar, Nathalie, et al.
Publicado: (2020) -
Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance
por: Habel, N, et al.
Publicado: (2013)